Regulation of entheseal IL-23 expression by IL-4 and IL-13 as an explanation for arthropathy development under dupilumab therapy
Abstract Objectives Dupilumab blocks the IL-4 receptor (IL-4R) and thus signalling of the ‘Th2’ cytokines IL-4 and IL-13. It has a license to treat atopic eczema and was recently linked to emergent enthesitis and psoriasis. We investigated the cellular and functional basis for how IL-4/IL-13 regulat...
Saved in:
Published in | Rheumatology (Oxford, England) Vol. 60; no. 5; pp. 2461 - 2466 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Oxford University Press
14.05.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Abstract
Objectives
Dupilumab blocks the IL-4 receptor (IL-4R) and thus signalling of the ‘Th2’ cytokines IL-4 and IL-13. It has a license to treat atopic eczema and was recently linked to emergent enthesitis and psoriasis. We investigated the cellular and functional basis for how IL-4/IL-13 regulates the IL-23–IL-17 axis in entheseal stromal, myeloid and lymphocyte cells.
Methods
Immunohistochemistry was performed on healthy enthesis samples from patients undergoing elective spinal surgery to investigate entheseal tissue IL-4R expression and cytokine expression by intracellular flow cytometry for IL-4 and IL-13. Digested human enthesis samples were stimulated with lipopolysaccharide (LPS) for IL-23 induction, either alone or with IL-4 or IL-13. Enthesis fibroblasts were stimulated with TNF and IL-17 with and without IL-4 or IL-13 to assess the effect on CCL20 secretion. Synovial fluid samples from PsA patients were also analysed by ELISA for levels of IL-4 and IL-13.
Results
The IL-4/IL-13 receptor was present in both the peri-entheseal bone and enthesis soft tissue, and entheseal-derived T cells produced basal levels of IL-4, but not IL-13. Both IL-4 and IL-13 attenuated LPS-induced entheseal IL-23 production. IL-4 also downregulated secretion of TNF/IL-17A-induced CCL20 from entheseal fibroblasts. Both IL-13 and IL-4 were also detectable in the synovial fluid of PsA patients. We also noted a seronegative inflammatory oligoarthritis whilst under dupilumab therapy.
Conclusion
Our findings suggest a previously unknown protective role for IL-4/IL-13 in entheseal induction of the IL-23–IL-17 axis. These findings point towards a novel explanation for IL-13 pathway single nucleotide polymorphisms in PsA and also a molecular explanation for why anti-IL-4/IL-13 therapy may induce musculoskeletal entheseal pathology as recently reported. |
---|---|
AbstractList | OBJECTIVESDupilumab blocks the IL-4 receptor (IL-4R) and thus signalling of the 'Th2' cytokines IL-4 and IL-13. It has a license to treat atopic eczema and was recently linked to emergent enthesitis and psoriasis. We investigated the cellular and functional basis for how IL-4/IL-13 regulates the IL-23-IL-17 axis in entheseal stromal, myeloid and lymphocyte cells. METHODSImmunohistochemistry was performed on healthy enthesis samples from patients undergoing elective spinal surgery to investigate entheseal tissue IL-4R expression and cytokine expression by intracellular flow cytometry for IL-4 and IL-13. Digested human enthesis samples were stimulated with lipopolysaccharide (LPS) for IL-23 induction, either alone or with IL-4 or IL-13. Enthesis fibroblasts were stimulated with TNF and IL-17 with and without IL-4 or IL-13 to assess the effect on CCL20 secretion. Synovial fluid samples from PsA patients were also analysed by ELISA for levels of IL-4 and IL-13. RESULTSThe IL-4/IL-13 receptor was present in both the peri-entheseal bone and enthesis soft tissue, and entheseal-derived T cells produced basal levels of IL-4, but not IL-13. Both IL-4 and IL-13 attenuated LPS-induced entheseal IL-23 production. IL-4 also downregulated secretion of TNF/IL-17A-induced CCL20 from entheseal fibroblasts. Both IL-13 and IL-4 were also detectable in the synovial fluid of PsA patients. We also noted a seronegative inflammatory oligoarthritis whilst under dupilumab therapy. CONCLUSIONOur findings suggest a previously unknown protective role for IL-4/IL-13 in entheseal induction of the IL-23-IL-17 axis. These findings point towards a novel explanation for IL-13 pathway single nucleotide polymorphisms in PsA and also a molecular explanation for why anti-IL-4/IL-13 therapy may induce musculoskeletal entheseal pathology as recently reported. Abstract Objectives Dupilumab blocks the IL-4 receptor (IL-4R) and thus signalling of the ‘Th2’ cytokines IL-4 and IL-13. It has a license to treat atopic eczema and was recently linked to emergent enthesitis and psoriasis. We investigated the cellular and functional basis for how IL-4/IL-13 regulates the IL-23–IL-17 axis in entheseal stromal, myeloid and lymphocyte cells. Methods Immunohistochemistry was performed on healthy enthesis samples from patients undergoing elective spinal surgery to investigate entheseal tissue IL-4R expression and cytokine expression by intracellular flow cytometry for IL-4 and IL-13. Digested human enthesis samples were stimulated with lipopolysaccharide (LPS) for IL-23 induction, either alone or with IL-4 or IL-13. Enthesis fibroblasts were stimulated with TNF and IL-17 with and without IL-4 or IL-13 to assess the effect on CCL20 secretion. Synovial fluid samples from PsA patients were also analysed by ELISA for levels of IL-4 and IL-13. Results The IL-4/IL-13 receptor was present in both the peri-entheseal bone and enthesis soft tissue, and entheseal-derived T cells produced basal levels of IL-4, but not IL-13. Both IL-4 and IL-13 attenuated LPS-induced entheseal IL-23 production. IL-4 also downregulated secretion of TNF/IL-17A-induced CCL20 from entheseal fibroblasts. Both IL-13 and IL-4 were also detectable in the synovial fluid of PsA patients. We also noted a seronegative inflammatory oligoarthritis whilst under dupilumab therapy. Conclusion Our findings suggest a previously unknown protective role for IL-4/IL-13 in entheseal induction of the IL-23–IL-17 axis. These findings point towards a novel explanation for IL-13 pathway single nucleotide polymorphisms in PsA and also a molecular explanation for why anti-IL-4/IL-13 therapy may induce musculoskeletal entheseal pathology as recently reported. Dupilumab blocks the IL-4 receptor (IL-4R) and thus signalling of the 'Th2' cytokines IL-4 and IL-13. It has a license to treat atopic eczema and was recently linked to emergent enthesitis and psoriasis. We investigated the cellular and functional basis for how IL-4/IL-13 regulates the IL-23-IL-17 axis in entheseal stromal, myeloid and lymphocyte cells. Immunohistochemistry was performed on healthy enthesis samples from patients undergoing elective spinal surgery to investigate entheseal tissue IL-4R expression and cytokine expression by intracellular flow cytometry for IL-4 and IL-13. Digested human enthesis samples were stimulated with lipopolysaccharide (LPS) for IL-23 induction, either alone or with IL-4 or IL-13. Enthesis fibroblasts were stimulated with TNF and IL-17 with and without IL-4 or IL-13 to assess the effect on CCL20 secretion. Synovial fluid samples from PsA patients were also analysed by ELISA for levels of IL-4 and IL-13. The IL-4/IL-13 receptor was present in both the peri-entheseal bone and enthesis soft tissue, and entheseal-derived T cells produced basal levels of IL-4, but not IL-13. Both IL-4 and IL-13 attenuated LPS-induced entheseal IL-23 production. IL-4 also downregulated secretion of TNF/IL-17A-induced CCL20 from entheseal fibroblasts. Both IL-13 and IL-4 were also detectable in the synovial fluid of PsA patients. We also noted a seronegative inflammatory oligoarthritis whilst under dupilumab therapy. Our findings suggest a previously unknown protective role for IL-4/IL-13 in entheseal induction of the IL-23-IL-17 axis. These findings point towards a novel explanation for IL-13 pathway single nucleotide polymorphisms in PsA and also a molecular explanation for why anti-IL-4/IL-13 therapy may induce musculoskeletal entheseal pathology as recently reported. |
Author | Loughenbury, Peter Bridgewood, Charlie Watad, Abdulla Sharif, Kassem Freeston, Jane Russell, Tobias McGonagle, Dennis Wittmann, Miriam Saleem, Benazir Rao, Abhay Khan, Almas |
Author_xml | – sequence: 1 givenname: Charlie surname: Bridgewood fullname: Bridgewood, Charlie organization: Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK – sequence: 2 givenname: Kassem surname: Sharif fullname: Sharif, Kassem organization: Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK – sequence: 3 givenname: Jane surname: Freeston fullname: Freeston, Jane organization: Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK – sequence: 4 givenname: Benazir surname: Saleem fullname: Saleem, Benazir organization: Leeds Teaching Hospitals NHS Trust – sequence: 5 givenname: Tobias surname: Russell fullname: Russell, Tobias organization: Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK – sequence: 6 givenname: Abdulla surname: Watad fullname: Watad, Abdulla organization: Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK – sequence: 7 givenname: Almas surname: Khan fullname: Khan, Almas organization: Leeds Teaching Hospitals NHS Trust – sequence: 8 givenname: Peter surname: Loughenbury fullname: Loughenbury, Peter organization: Leeds Teaching Hospitals NHS Trust – sequence: 9 givenname: Abhay surname: Rao fullname: Rao, Abhay organization: Leeds Teaching Hospitals NHS Trust – sequence: 10 givenname: Miriam surname: Wittmann fullname: Wittmann, Miriam organization: Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK – sequence: 11 givenname: Dennis surname: McGonagle fullname: McGonagle, Dennis email: d.g.mcgonagle@leeds.ac.uk organization: Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33253386$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkE1P3DAQhi1ExVf7DxDykUtYO_6Ic0SIFqSVkKr2HI3jCbuQxMFOUHPjp9fRLogjp5nxPPPO-D0lh73vkZBzzq44K8UqbHDqYPStf5xXzwigtDkgJ1zqPGNC5IcfeS6PyWmMT4wxxYU5IseprYQw-oS8_cbHqYVx63vqG4r9uMGI0NL7dZYLiv-GgDEuXTsvb5JC75aECwoxFQvSQr9TaHygEMZN8AOMm5k6fMXWD12SpVPvMFA3Dds23W1pWhRgmL-Tbw20EX_s4xn5-_P2z81dtn74dX9zvc5qoaXOoG50rYUSxhpbWudMwTkrVGFdWaRv1q6GJudgmDJKWQ2l5I2xouBFLkvQ4oxc7nSH4F8mjGPVbWONbbod_RSrXGrNZM5VkVC5Q-vgYwzYVEPYdhDmirNq8b767H219z6NXew3TLZD9zH0bnYCVjvAT8PXJP8Ded2X6A |
CitedBy_id | crossref_primary_10_1016_j_medcle_2023_05_022 crossref_primary_10_4081_dr_2023_9839 crossref_primary_10_3390_ijms23031104 crossref_primary_10_1007_s12016_022_08934_0 crossref_primary_10_1016_j_xjidi_2021_100042 crossref_primary_10_1016_j_rmr_2024_04_001 crossref_primary_10_1111_ajd_13676 crossref_primary_10_1016_j_jaci_2021_11_014 crossref_primary_10_1016_j_medcli_2023_05_020 crossref_primary_10_53986_ibjm_2024_0011 crossref_primary_10_1097_ACI_0000000000000926 crossref_primary_10_1159_000530608 crossref_primary_10_1016_j_jid_2022_10_015 crossref_primary_10_3390_cells10020341 crossref_primary_10_1007_s40257_023_00837_w crossref_primary_10_1111_1346_8138_15872 crossref_primary_10_1080_09546634_2023_2242540 crossref_primary_10_1093_rheumatology_keab771 crossref_primary_10_1016_j_jaci_2023_08_024 crossref_primary_10_1016_j_det_2024_02_011 crossref_primary_10_1016_j_jid_2022_03_013 crossref_primary_10_1016_j_jdcr_2021_12_011 crossref_primary_10_3389_falgy_2024_1368259 crossref_primary_10_1007_s40278_021_02112_0 crossref_primary_10_1089_derm_2022_0096 crossref_primary_10_1111_bjd_20138 crossref_primary_10_1093_ced_llad390 crossref_primary_10_3389_fendo_2024_1227196 crossref_primary_10_1007_s00281_021_00836_1 crossref_primary_10_1080_07853890_2023_2280991 crossref_primary_10_3390_cells13090743 crossref_primary_10_1007_s40257_023_00804_5 crossref_primary_10_1007_s13555_023_01082_z crossref_primary_10_1177_20587392221076450 |
Cites_doi | 10.1111/bjd.18031 10.1016/j.jdcr.2020.01.012 10.1111/jdv.16239 10.1172/JCI7739 10.1002/eji.1830261020 10.1097/DER.0000000000000481 10.1007/s10067-019-04683-2 10.1186/1755-1536-3-9 10.1038/nrrheum.2017.188 10.1016/j.jaci.2018.05.029 10.1073/pnas.1416922112 10.1016/j.jid.2020.03.965 10.1056/NEJMoa1314768 10.1038/s41467-018-06933-4 10.1136/ard.2010.143123 10.1084/jem.20071397 10.1111/ced.14050 10.4049/jimmunol.159.11.5687 10.1136/annrheumdis-2018-214944 10.1038/nrrheum.2015.53 10.1080/1744666X.2017.1298443 |
ContentType | Journal Article |
Copyright | The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com 2020 The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com. |
Copyright_xml | – notice: The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com 2020 – notice: The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com. |
DBID | NPM AAYXX CITATION 7X8 |
DOI | 10.1093/rheumatology/keaa568 |
DatabaseName | PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic CrossRef PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1462-0332 |
EndPage | 2466 |
ExternalDocumentID | 10_1093_rheumatology_keaa568 33253386 10.1093/rheumatology/keaa568 |
Genre | Journal Article |
GroupedDBID | --- -E4 .2P .GJ .I3 .XZ .ZR 08P 0R~ 18M 1TH 29P 2WC 354 3O- 4.4 48X 53G 5RE 5VS 5WA 5WD 70D AABZA AACZT AAGKA AAJKP AAJQQ AAMDB AAMVS AAOGV AAPGJ AAPNW AAPQZ AAPXW AARHZ AASNB AAUAY AAUQX AAVAP AAWDT AAWTL ABEUO ABIXL ABJNI ABKDP ABLJU ABNHQ ABNKS ABOCM ABPTD ABQLI ABQNK ABQTQ ABXVV ABZBJ ACFRR ACGFO ACGFS ACPRK ACUFI ACUTJ ACUTO ACYHN ADBBV ADEYI ADEZT ADGZP ADHKW ADHZD ADIPN ADJQC ADOCK ADQBN ADRIX ADRTK ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AENEX AENZO AEPUE AETBJ AEWNT AFFNX AFFZL AFIYH AFOFC AFXAL AFXEN AGINJ AGKEF AGSYK AGUTN AHMBA AHXPO AIAGR AIJHB AJEEA AKWXX ALMA_UNASSIGNED_HOLDINGS ALUQC APIBT APWMN AQDSO ATGXG ATTQO AXUDD AZFZN BAWUL BAYMD BCRHZ BEYMZ BHONS BTRTY BVRKM C45 CAG CDBKE COF CS3 CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBD EBS EE~ EIHJH EJD EMOBN ENERS F5P F9B FECEO FEDTE FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HVGLF HW0 HZ~ IOX J21 KAQDR KBUDW KC5 KOP KQ8 KSI KSN L7B M-Z M49 MHKGH N9A NGC NOMLY NOYVH NTWIH NU- NVLIB O0~ O9- OAUYM OAWHX OBH OCZFY ODMLO OHH OJQWA OJZSN OK1 OPAEJ OVD OWPYF O~Y P2P PAFKI PB- PEELM PQQKQ Q1. Q5Y R44 RD5 RHF RIG RNI ROL ROX RUSNO RW1 RXO RZF RZO SV3 TCURE TEORI TJX TMA TR2 VVN W8F WOQ X7H YAYTL YKOAZ YXANX ZGI ZKX ZY1 ~91 ACIMA AIMBJ ASMCH AWCFO BGYMP BYORX NPM AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c3646-acf6c63538b8b9bdd87110757bd97462cdcaf21a805855b6a941f8b3717249a63 |
ISSN | 1462-0324 |
IngestDate | Thu Aug 15 23:29:34 EDT 2024 Fri Aug 23 00:36:59 EDT 2024 Thu May 23 23:45:58 EDT 2024 Wed Aug 28 03:18:56 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | IL-4 enthesitis atopic dermatitis IL-13 dupilumab |
Language | English |
License | This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model) The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c3646-acf6c63538b8b9bdd87110757bd97462cdcaf21a805855b6a941f8b3717249a63 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 33253386 |
PQID | 2466042157 |
PQPubID | 23479 |
PageCount | 6 |
ParticipantIDs | proquest_miscellaneous_2466042157 crossref_primary_10_1093_rheumatology_keaa568 pubmed_primary_33253386 oup_primary_10_1093_rheumatology_keaa568 |
PublicationCentury | 2000 |
PublicationDate | 2021-May-14 |
PublicationDateYYYYMMDD | 2021-05-14 |
PublicationDate_xml | – month: 05 year: 2021 text: 2021-May-14 day: 14 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Rheumatology (Oxford, England) |
PublicationTitleAlternate | Rheumatology (Oxford) |
PublicationYear | 2021 |
Publisher | Oxford University Press |
Publisher_xml | – name: Oxford University Press |
References | Beck (2021051419004884900_keaa568-B4) 2014; 371 Murata (2021051419004884900_keaa568-B3) 1998; 1 Courneya (2021051419004884900_keaa568-B15) 2010; 3 Schett (2021051419004884900_keaa568-B1) 2017; 13 Gandhi (2021051419004884900_keaa568-B2) 2017; 13 Fowler (2021051419004884900_keaa568-B9) 2019; 30 Varma (2021051419004884900_keaa568-B8) 2020; 6 Horsfall (2021051419004884900_keaa568-B17) 1997; 159 Bowes (2021051419004884900_keaa568-B10) 2011; 70 Bridgewood (2021051419004884900_keaa568-B11) 2019; 78 Hirota (2021051419004884900_keaa568-B16) 2007; 204 Wijs (2021051419004884900_keaa568-B6) 2020; 45 Bessis (2021051419004884900_keaa568-B19) 1996; 26 Lubberts (2021051419004884900_keaa568-B20) 2015; 11 Willsmore (2021051419004884900_keaa568-B5) 2019; 181 Shi (2021051419004884900_keaa568-B13) 2020 Ishibashi (2021051419004884900_keaa568-B7) 2020; 34 Wollenberg (2021051419004884900_keaa568-B22) 2019; 143 Cambré (2021051419004884900_keaa568-B12) 2018; 9 Girolimetto (2021051419004884900_keaa568-B14) 2020; 39 Guenova (2021051419004884900_keaa568-B21) 2015; 112 Lubberts (2021051419004884900_keaa568-B18) 2000; 105 |
References_xml | – volume: 181 start-page: 1068 year: 2019 ident: 2021051419004884900_keaa568-B5 article-title: Development of inflammatory arthritis and enthesitis in patients on dupilumab: a case series publication-title: Br J Dermatol doi: 10.1111/bjd.18031 contributor: fullname: Willsmore – volume: 6 start-page: 217 year: 2020 ident: 2021051419004884900_keaa568-B8 article-title: Dupilumab-induced phenotype switching from atopic dermatitis to psoriasis publication-title: JAAD Case Rep doi: 10.1016/j.jdcr.2020.01.012 contributor: fullname: Varma – volume: 34 start-page: e319 year: 2020 ident: 2021051419004884900_keaa568-B7 article-title: Polyenthesitis during treatment with dupilumab for atopic dermatitis publication-title: J Eur Acad Dermatol Venereol doi: 10.1111/jdv.16239 contributor: fullname: Ishibashi – volume: 105 start-page: 1697 year: 2000 ident: 2021051419004884900_keaa568-B18 article-title: IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion publication-title: J Clin Invest doi: 10.1172/JCI7739 contributor: fullname: Lubberts – volume: 26 start-page: 2399 year: 1996 ident: 2021051419004884900_keaa568-B19 article-title: Attenuation of collagen-induced arthritis in mice by treatment with vector cells engineered to secrete interleukin-13 publication-title: Eur J Immunol doi: 10.1002/eji.1830261020 contributor: fullname: Bessis – volume: 30 start-page: 234 year: 2019 ident: 2021051419004884900_keaa568-B9 article-title: Psoriasiform dermatitis after initiation of treatment with dupilumab for atopic dermatitis publication-title: Dermatitis doi: 10.1097/DER.0000000000000481 contributor: fullname: Fowler – volume: 1 start-page: 551 year: 1998 ident: 2021051419004884900_keaa568-B3 article-title: Structure of and signal transduction through interleukin-4 and interleukin-13 receptors publication-title: Int J Mol Med contributor: fullname: Murata – volume: 39 start-page: 1157 year: 2020 ident: 2021051419004884900_keaa568-B14 article-title: Predominant ultrasonographic extracapsular changes in symptomatic psoriatic dactylitis: results from a multicenter cross-sectional study comparing symptomatic and asymptomatic hand dactylitis publication-title: Clin Rheumatol doi: 10.1007/s10067-019-04683-2 contributor: fullname: Girolimetto – volume: 3 start-page: 9 year: 2010 ident: 2021051419004884900_keaa568-B15 article-title: Interleukins 4 and 13 modulate gene expression and promote proliferation of primary human tenocytes publication-title: Fibrogenesis Tissue Repair doi: 10.1186/1755-1536-3-9 contributor: fullname: Courneya – volume: 13 start-page: 731 year: 2017 ident: 2021051419004884900_keaa568-B1 article-title: Enthesitis: from pathophysiology to treatment publication-title: Nat Rev Rheumatol doi: 10.1038/nrrheum.2017.188 contributor: fullname: Schett – volume: 143 start-page: 135 year: 2019 ident: 2021051419004884900_keaa568-B22 article-title: Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2018.05.029 contributor: fullname: Wollenberg – volume: 112 start-page: 2163 year: 2015 ident: 2021051419004884900_keaa568-B21 article-title: IL-4 abrogates TH17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cells publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1416922112 contributor: fullname: Guenova – year: 2020 ident: 2021051419004884900_keaa568-B13 article-title: Differential requirement for CCR6 in IL-23-mediated skin and joint inflammation publication-title: J Invest Dermatol doi: 10.1016/j.jid.2020.03.965 contributor: fullname: Shi – volume: 371 start-page: 130 year: 2014 ident: 2021051419004884900_keaa568-B4 article-title: Dupilumab treatment in adults with moderate-to-severe atopic dermatitis publication-title: N Engl J Med doi: 10.1056/NEJMoa1314768 contributor: fullname: Beck – volume: 9 start-page: 4613 year: 2018 ident: 2021051419004884900_keaa568-B12 article-title: Mechanical strain determines the site-specific localization of inflammation and tissue damage in arthritis publication-title: Nat Commun doi: 10.1038/s41467-018-06933-4 contributor: fullname: Cambré – volume: 70 start-page: 1016 year: 2011 ident: 2021051419004884900_keaa568-B10 article-title: Evidence to support IL-13 as a risk locus for psoriatic arthritis but not psoriasis vulgaris publication-title: Ann Rheum Dis doi: 10.1136/ard.2010.143123 contributor: fullname: Bowes – volume: 204 start-page: 2803 year: 2007 ident: 2021051419004884900_keaa568-B16 article-title: Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model publication-title: J Exp Med doi: 10.1084/jem.20071397 contributor: fullname: Hirota – volume: 45 start-page: 262 year: 2020 ident: 2021051419004884900_keaa568-B6 article-title: Acute arthritis and arthralgia as an adverse drug reaction to dupilumab publication-title: Clin Exp Dermatol doi: 10.1111/ced.14050 contributor: fullname: Wijs – volume: 159 start-page: 5687 year: 1997 ident: 2021051419004884900_keaa568-B17 article-title: Suppression of collagen-induced arthritis by continuous administration of IL-4 publication-title: J immunol doi: 10.4049/jimmunol.159.11.5687 contributor: fullname: Horsfall – volume: 78 start-page: 929 year: 2019 ident: 2021051419004884900_keaa568-B11 article-title: Identification of myeloid cells in the human enthesis as the main source of local IL-23 production publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2018-214944 contributor: fullname: Bridgewood – volume: 11 start-page: 415 year: 2015 ident: 2021051419004884900_keaa568-B20 article-title: The IL-23–IL-17 axis in inflammatory arthritis publication-title: Nat Rev Rheumatol doi: 10.1038/nrrheum.2015.53 contributor: fullname: Lubberts – volume: 13 start-page: 425 year: 2017 ident: 2021051419004884900_keaa568-B2 article-title: Commonality of the IL-4/IL-13 pathway in atopic diseases publication-title: Expert Rev Clin Immunol doi: 10.1080/1744666X.2017.1298443 contributor: fullname: Gandhi |
SSID | ssj0005138 |
Score | 2.5174813 |
Snippet | Abstract
Objectives
Dupilumab blocks the IL-4 receptor (IL-4R) and thus signalling of the ‘Th2’ cytokines IL-4 and IL-13. It has a license to treat atopic... Dupilumab blocks the IL-4 receptor (IL-4R) and thus signalling of the 'Th2' cytokines IL-4 and IL-13. It has a license to treat atopic eczema and was recently... OBJECTIVESDupilumab blocks the IL-4 receptor (IL-4R) and thus signalling of the 'Th2' cytokines IL-4 and IL-13. It has a license to treat atopic eczema and was... |
SourceID | proquest crossref pubmed oup |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 2461 |
Title | Regulation of entheseal IL-23 expression by IL-4 and IL-13 as an explanation for arthropathy development under dupilumab therapy |
URI | https://www.ncbi.nlm.nih.gov/pubmed/33253386 https://search.proquest.com/docview/2466042157 |
Volume | 60 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1baxQxFA5rhdIX8e56I4IPwpJ2M8ncHq2otbQ-aAv7NiSZhC6ts8tewPbJn-JP9eQyM1mrUH0ZdpIhYeb7NjlJvnMOQq8tyrQ0nKS1zgnPTU0Eo5SoWiY8M1QJbh2Fjz9nB6f8cJJOBoOfkWppvZK76uqPfiX_gyqUAa7WS_YfkO0ahQL4DfjCFRCG640w_uITyQebD6aPM6ujuxh9OiIJs8H7vci1sTYmlHEv_j0ilNn0MsLF978QTa83hD5s2gSwCi9bdyonFrCeZotRvZ5PYSwTcrSKYhG00b3PNFStfEgnG8P0eyubD3lCoj2Hfecl1qp93In_tCOYDSE9NV7psVyGnWXnn6L1Moj9D0WvBvgKU5x2rN7XjbiaLuKNjITaM3jvQLqr_eDLs4SMGdsYnX22gcDCNB5quY_ifm0O8PGxFtFbw-25FiL1CXwiYsy_OWZAl2D1_h6S20_yoeoWup3kZWqX9x8nkYiIsqJ1yCzZXtzpXuhyB223jWzYPhv-lNeWNc68ObmL7oR1CX7rSXYPDXRzH20fB-XFA_Sj5xqeGdxxDTuu4Z5rWF7aMo4Bcuy4hsUSbnDENQzUwBHXcMQ17LiGO67hwLWH6PTD-5N3ByRk7yCKZTwjQplMgTnLClnIUtY1LM0pGKi5rGENmyWqVsIkVBRjWLGmMhMlp6aQLAeTmpciY4_QVjNr9BOE4TltlKjVWJecF0YaJgtVykQazVIth4i037Wa-yAtlRdXsCqGpAqQDNEb-Pg3fPRVi1AFA689TQOGz9bLCviXwYxH03yIHnvouhZbwJ_-teYZ2un_A8_R1mqx1i_AvF3Jl45hvwCI460I |
link.rule.ids | 315,786,790,27957,27958 |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Regulation+of+entheseal+IL-23+expression+by+IL-4+and+IL-13+as+an+explanation+for+arthropathy+development+under+dupilumab+therapy&rft.jtitle=Rheumatology+%28Oxford%2C+England%29&rft.au=Bridgewood%2C+Charlie&rft.au=Sharif%2C+Kassem&rft.au=Freeston%2C+Jane&rft.au=Saleem%2C+Benazir&rft.date=2021-05-14&rft.eissn=1462-0332&rft.volume=60&rft.issue=5&rft.spage=2461&rft_id=info:doi/10.1093%2Frheumatology%2Fkeaa568&rft_id=info%3Apmid%2F33253386&rft.externalDocID=33253386 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1462-0324&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1462-0324&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1462-0324&client=summon |